accessibilityalertarrow-downarrow-leftarrow-rightarrow-upchevron-downchevron-leftchevron-rightchevron-upclosedigital-transformationdiversitydownloaddrivedropboxeventsexitexpandfacebookguideinstagramjob-pontingslanguage-selectorlanguagelinkedinlocationmailmenuminuspencilphonephotoplayplussearchsharesoundshottransactionstwitteruploadwebinarwp-searchwt-arrowyoutube
Press Release Press Release

Wolf Theiss advises Fareva on the acquisition of a production site of the Novartis Group

The Wolf Theiss Team consisted of Consultant Melanie Dimitrov/Tax, Partner Christian Hoenig/Corporate/M&A and Partner Karl Binder/Real Estate & Construction.

Fareva is a leading contract service provider in the industrial sector and offers, among other things, research, manufacturing and packaging solutions for the pharmaceutical industry. With the acquisition of the site in Unterach, Fareva will further strengthen its presence in the European market, especially in the area of ready-to-inject pharmaceuticals manufacturing. The site is considered a centre of excellence for the manufacture of injectable cancer drugs and will continue to produce for the Novartis Group. A corresponding supply agreement is part of the contractual agreement.

Read the full text

Download PDF

Contributors